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Background: Fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) are poorly
absorbed, short-chain carbohydrates that play an important role in inducing functional gut symptoms. A low-FODMAP
diet improves abdominal symptoms in patients with inflammatory bowel disease and irritable bowel syndrome.
However, there were no study for the effect of FODMAP content on gastrointestinal intolerance and nutritional status
in patients receiving enteral nutrition (EN).
Methods: In this randomized, multicenter, double-blind, 14-day clinical trial, eligible hospitalized patients receiving
EN (n = 100) were randomly assigned to three groups; 84 patients completed the trial (low-FODMAP EN, n = 30;
moderate-FODMAP EN, n = 28; high-FODMAP EN, n = 26). Anthropometric and biochemical parameters were
measured; stool assessment was performed using the King’s Stool Chart and clinical definition.
Results: Baseline values were not significantly different among the three groups. After the 14-day intervention, diarrhea
significantly improved in the low-FODMAP group than in the moderate- and high-FODMAP groups (P < 0.05). King’s
Stool scores in diarrhea subjects were significantly and steadily reduced in the low-FODMAP group compared with the
other two groups (P for time and EN type interaction <0.05). BMI increased significantly in the low- and high-FODMAP
groups during the intervention (P < 0.05 for both), and showed a trend toward increasing in the moderate-FODMAP
group (P < 0.10). Serum prealbumin increased significantly in all groups by 14-day; by 3-day, it had increased to the levels
at 14-day in the low-FODMAP group. At 14-day, serum transferrin had increased significantly in the moderate-FODMAP
group. In addition, subjects were classified by final condition (unimproved, normal maintenance, diarrhea only improved,
constipation only improved, and recurrent diarrhea/constipation improved). Seventy-five percent of the diarrhea
improved group consumed the low-FODMAP EN formula. 38.5 and 46.2 % of recurrent diarrhea/constipation improved
group consumed the low- and moderate-FODMAP EN respectively. BMI significantly increased in all groups except the
unimproved. Prealbumin levels significantly increased in the diarrhea-improved and recurrent diarrhea/constipation
groups at 3-day and continued by 14-day, and in the constipation-improved group at 14-day. Transferrin levels
significantly increased in the diarrhea-improved and recurrent diarrhea/constipation groups at 14-day.
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Conclusion: Low-FODMAP EN may improve diarrhea, leading to improved nutritional status and facilitating prompt
recovery from illness.
Keywords: Poorly absorbed, Short-chain carbohydrates, Enteral nutrition, Diarrhea, Prealbumin, Transferrin,
body mass indexBackground
Enteral nutrition (EN) is a common method of nutri-
tion support for hospitalized patients with intact
gastrointestinal function who are unable to eat or
whose nutritional requirements are not satisfied with
an oral diet [1]. Despite the benefits of EN (e.g.,
shortening the length of hospital stays and lowering
rates of infectious complications, readmissions, and
mortality) [2–4], gastrointestinal symptoms, such as
diarrhea, constipation, bloating, abdominal pain, flatu-
lence, and vomiting/nausea, frequently occur [5].
These symptoms may cause malnutrition (i.e., imbal-
anced fluid and electrolytes and/or inadequate intake/
absorption of nutrients), thereby preventing prompt
recovery from illness [6, 7]. Diarrhea, in particular, is
a frequently observed gastrointestinal symptom in pa-
tients receiving EN [8–10]: it occurs in anywhere of
hospitalized EN patients, depending on their health
[11–13]. The cause of EN-associated diarrhea is un-
clear, but likely multifactorial. Absorption problems,
feeding temperature, feeding method, and the high
osmolality and nutrient composition of EN formulas
are probable factors [14–19]. Many have endeavored
to solve the problem by changing feeding method,
temperature, or formula content [6], but the results
have been inconsistent.
Recently, it has been suggested that diarrhea is associ-
ated with fermentable oligosaccharides, disaccharides,
monosaccharides, and polyols (FODMAPs) which is
poorly absorbed, short-chain carbohydrates [8, 9, 20–23].
FODMAPs are found in a wide variety of foods, including
apples, mangos, and fructose syrup (fructose); onions, gar-
lic, and rye (fructans); milk (lactose); legumes (galactans);
and mushrooms, stone fruit, and some artificial sweet-
eners (polyols) [24]. They are poorly absorbed in the small
intestine and, when delivered to the colon, may produce
gas and subsequently cause luminal distension, disturb gut
motility, and result in diarrhea [23–25]. A low-FODMAP
diet significantly reduces gastrointestinal symptoms in
patients with irritable bowel syndrome (IBS) and inflam-
matory bowel disease (IBD) [20–23, 26]. Of note, low-
FODMAP dietary interventions improve gastrointestinal
symptoms more in IBS patients with fructose malabsorp-
tion problems than in those without [22]. A retrospective
EN study reported that the rate of diarrhea development
was lower in patients given a lower-FODMAP formulathan those given other types of formulas [8]: although
length of hospital stay and duration of EN independently
predicted diarrhea development, this study suggested that
being provided with a lower-FODMAP formula could po-
tentially mitigate these risks [8, 9].
To date, all the intervention studies for the association
between gastrointestinal symptom and FODMAPs were
performed in the patients with IBS or IBD, however
there has been no prospective intervention study investi-
gating the effect of FODMAP content on diarrhea and
nutritional status in patients receiving EN. Therefore,
this randomized, double-blind 14-day clinical trial inves-
tigated the effect of FODMAP content in EN formula on
gastrointestinal intolerance and nutritional status in hos-
pitalized patients receiving EN.
Materials and methods
Study design and participants
This study was a randomized, multicenter, double-blind,
14-day clinical trial. Between November 2013 and
November 2014, participants were recruited from 10
hospitals located in Busan and its environs, in the Re-
public of Korea. Five were university hospitals (Dong-A
University Hospital, Busan National University Hospital
and Dong-Eui Medical Center in Busan, and Busan
National University Hospital in Yangsan) and six were
rehabilitation and long-term care hospitals (Bumin Hos-
pital, Centum Erooda Hospital, Happy Medical Center,
Inchang Hospital, Keunsol Medical Hospital, and Med-
will hospital in Busan). All participants aged 20 years or
over were hospitalized and receiving EN. Exclusion cri-
teria included the following: 1) EN forbidden due to
ileus, gastrectomy, bleeding in the digestive tract, etc.; 2)
renal or liver dysfunction, e.g., renal failure, nephritis,
nephrotic syndrome, hepatitis, cirrhosis, serum creatin-
ine > 1.5 mg/dl, serum urea nitrogen > 25 mg/ml, serum
aspartate aminotransferase > 40U/L, or serum alanine
aminotransferase > 40U/L; 3) uncontrollable diabetes;
and 4) pregnancy or breast-feeding. All study partici-
pants (or their legal guardians) were provided with de-
tailed information about the study and provided written
informed consent. One hundred sixty five subjects were
assessed for eligibility. One-hundred eligible subjects
were randomly assigned to low-FODMAP EN,
moderate-FODMAP EN, or high-FODMAP EN for
14 days using a block randomization method. The
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to the contents of the experimental EN formulas. The
experimental EN formulas were indistinguishable color
and provided in identical cans. Allocation concealment
was maintained using a centralized, web-based
randomization schedule accessible 24 h a day. Energy
needs were estimated by a registered dietitian (RD)
based on the patient’s height, weight and disease condi-
tion. Basically, patients received intermittent nasogastric
EN feeding (100–400 ml/20–40 min, 3 times/day). To
avoid unexpected gastrointestinal problems due to a
sudden change in EN formula, each patient basically had
a 3-day adaptation period in which one-third the volume
of the former formula was replaced with the new, ex-
perimental EN formula each day. Sixteen participants
dropped out during the intervention period, leaving 84
to complete the study. Of the 16 dropouts, 2 were trans-
ferred to another hospital, 2 stopped EN and changed to
a transitional diet, 4 severe diarrheas and 8 withdrew for
personal reasons. Finally, 84 patients completed the trial
(low-FODMAP EN, n = 30; moderate-FODMAP EN, n =
28; high-FODMAP EN, n = 26) were included for ana-
lysis. The study protocol was approved by the Institu-
tional Review Board of Dong-A University (the
representative, approval no. 2-1040709-AB-N-01-
201310-BR-03-03) and carried out in accordance with
the Helsinki Declaration. The study’s clinicaltrial.gov
identifier is NCT02353689.Nutrient composition of experimental enteral nutrition
(EN) formulas
Three types of EN formula were provided by Dr.
Chung’s Foods Co., Ltd. (Cheongju, Chungbuk, Republic
of Korea); the FODMAP content and nutrient compos-
ition of each are described in Table 1. All the experimen-
tal EN formulas contained the same number of calories
per can (200 kcal/200 ml), but different FODMAP con-
tents (low-FODMAP: 0.320 g/can; moderate-FODMAP:
0.753 g/can; high-FODMAP: 1.222 g/can). Most of nu-
trient contents except some micronutrients are similar
in all the EN formulas and they were formulated follow-
ing to and within the guideline of Korean dietary refer-
ence intakes.Data collection
Baseline data included: patient demographics (age, gen-
der, height and body weight), disease history, dietitian
assessment of nutritional requirement etc. Data were
collected daily for up to 14 days post-randomization for
stool assessment, energy intake, time taken to reach
100 % experimental EN feeding. Anthropometric and
biochemical parameters were also collected at 0-day (be-
fore starting), 3-day (4th day morning) and 14-day (afterthe intervention) for the monitoring of nutritional
status.
Outcomes
The primary outcome was the improvement of diarrhea
assessed by the King’s Stool chart and the clinical defin-
ition. Secondary outcomes were the levels of plasma pre-
albumin and transferrin, the markers for short-term
nutritional status. Other outcomes were changes of an-
thropometric parameters, other biochemical parameters
and other gastrointestinal symptoms.
Stool assessment
Stool assessment data were collected daily for up to
14 days. It was performed using the King’s Stool Chart,
which incorporates descriptors of stool frequency, weight,
and consistency, as previously described [27–29]. The
chart has been validated for use in free-living individuals,
patients at high-risk of diarrhea and patients receiving en-
teral nutrition [27.28]. Briefly, the chart comprises three
categories of stool weight (<100 g, 100–200 g, >200 g) and
four categories of stool consistency (hard and formed, soft
and formed, loose and unformed, liquid). This results in
12 possible combinations of stool weight and consistency,
each accompanied by a verbal and pictorial descriptor to
assist accurate characterization [27–29]. Each category is
also assigned an alphabetical code, so that physicians,
nurses, and dieticians can record and communicate fecal
output using standard verbal and pictorial descriptors.
Fecal frequency is incorporated by recording the code of
each feces passed; each category is assigned a score, enab-
ling the summation of all scores in a 24-h period to obtain
a daily fecal score. In this study, diarrhea was classified as
a daily fecal score of 15 or more. Diarrhea was also classi-
fied using a clinical definition: 1) unformed or liquid stools
for two or more days; or 2) unformed and liquid stools
(≥200 g) three times or more per day. Constipation was
defined as a condition of fewer than three bowel move-
ments per week or no defecation for three or more days,
requiring stool softeners or an enema at least once.
Anthropometric parameters, blood pressure, and blood
collection
Height and body weight were measured when possible
(62 of 84 patients). Body mass index (BMI) was cal-
culated as body weight divided by height squared (kg/
m2). Blood pressure (BP) was obtained from the left
arm of seated individuals with an automatic BP moni-
tor (HEM-7220, OMRON, Matsusaka, Japan) after a
short rest. Triceps skin fold thickness (TSF, cm), mid-
arm circumference (MAC, mm) and midarm muscle
circumference (MAMC [cm] = TSF [cm] – MAC
[cm] × 3.14) were also measured. Blood specimens
were collected three times over the intervention
Table 1 FODMAP content and nutrient composition of experimental EN formulas
Per can (200 mL) Low-FODMAP Moderate-FODMAP High-FODMAP
Calorie (kcal) 200 200 200
Total FODMAPs (g) 0.320 0.753 1.222
Fructose (g) - (N.D.) - -
Lactose (g) - - -
Raffinose (g) 0.079 0.229 0.285
Stachyose (g) - - 0.239
1-Kestose (g) - - 0.511
Nystose (g) - - -
1-Fructofuranosylnystose (g) 0.233 0.509 0.411
Carbohydrates (g) 28 32 31
Sugar (g) 0 1 2
Fiber (g) 3 3 4.3
Protein (g) 9 8 9
Fat (g) 7 6 6
Sodium (mg) 135 180 135
Vitamin A (μgRE) 225 140 150
Vitamin B1 (mg) 0.24 0.3 0.24
Vitamin B2 (mg) 0.3 0.36 0.3
Vitamin B6 (mg) 0.3 0.45 0.3
Vitamin B12 (μg) 0.96 1 0.48
Vitamin C (mg) 40 30 20
Vitamin D (μg) 1 1 1
Vitamin E (mg α-TE) 4.8 5 2
Vitamin K (μg) 15 11 15
Folic acid (μg) 80 75 80
Niacin (mg NE) 3.2 2.6 3.2
Biotin (μg) 6 6 6
Pantothenic acid (mg) 1 1 1
Calcium (mg) 150 140 140
Phosphorus (mg) 140 140 140
Magnesium (mg) 58 22 58
Zinc (mg) 4 2.4 2
Iron (mg) 2 2.3 2
Potassium (mg) 225 308.5 220
Manganese (mg) 0.8 0.4 0.7
Copper (mg) 0.16 0.23 0.16
Iodine (mg) 30 23 30
N.D. non-detected, NE niacin equivalents, α-TE α-tocopherol
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fast, venous blood specimens were collected in
EDTA-treated or plain tubes. The tubes were immedi-
ately placed on ice until they arrived at the analytical
laboratory (1–3 h). Blood specimens were then sepa-
rated into plasma and serum and stored at −80 °C
until analysis.Serum glucose, lipid profile, albumin, prealbumin,
transferrin and blood cell counts
Fasting glucose was measured using a glucose oxidase
method (Glucose Analyzer Beckman Instruments, Irvine,
CA, USA), as described in a previous report [30]. Serum
total cholesterol, triglycerides, and low-density lipopro-
tein (LDL) cholesterol levels were measured using
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analyzer (Hitachi Ltd., Tokyo, Japan), as described previ-
ously [31]. After precipitating serum chylomicrons,
LDL-cholesterol, and very low-density lipoprotein with
dextran sulfate-magnesium, the high-density lipoprotein
(HDL) cholesterol left in the supernatant was measured
using a previously described enzymatic method [31].
Serum fasting albumin, preabumin and transferrin were
measured using commercially available kits on a Hitachi
7150 Auto-analyzer (Hitachi Ltd., Tokyo, Japan). White
blood cell (WBC) and absolute lymphocyte (ALC)
counts were determined using the HORIBA ABX diag-
nostics system (HORIBA ABX SAS, Parc Euromedicine,
France).
Safety parameters: liver and kidney functions
Serum aspartate aminotransferase (AST) and alanine
aminotransferase (ALT) were measured using a modified
International Federation of Clinical Chemistry (IFCC)
UV method. Serum creatinine was measured with a kin-
etic colorimetric (Jaffe) assay. Serum concentrations of
blood urea nitrogen (BUN) and uric acid were measured
using a kinetic UV Assay.
Serum high-sensitivity C-reactive protein and plasma
interleukin-6, interleukin-1β, and tumor necrosis factor-α
Serum high-sensitivity C-reactive protein (hs-CRP)
was measured with an ADVIA 1650 system (Bayer,
Tarrytown, NY, USA) using a commercially available,
high-sensitivity CRP-Latex(II) X2 kit (Seiken Labora-
tories Ltd., Tokyo, Japan), which allows detection of
CRP in the 0.001–31 mg/dL range, as described in a
previous report [31]. Plasma concentrations of
interleukin-6 (IL-6), IL-1β, and tumor necrosis factor-
α (TNF-α) were measured using the Quantikine® HS
ELISA Kit (R&D systems, Inc., Minneapolis, MN,
USA), according to the manufacturer's instructions.
The resulting color reaction was measured using
the iMark™ microplate absorbance reader (Bio-Rad
Laboratories, Hercules, CA, USA). The wavelength
correction was set to 490 and 560 nm.
Statistical analysis
Statistical analyses were performed with Win SPSS v21.0
(SPSS Inc., Chicago, IL). Sample-size calculation was
based on the primary outcome, improvement of diarrhea
during the 14-day intervention period. A sample size of
25 subjects per group with a significance level of 0.05
yielded 95 % power, therefore 100 participants were en-
rolled to allow for over an estimated 70 % retention rate
across the study period. No stopping rules or interim
analyses were planned. Differences in continuous vari-
ables between the groups were assessed using one-way
analysis of variance (ANOVA) followed by theBonferroni correction. Differences in continuous vari-
ables within a group, before and after the intervention,
were analyzed using paired t-tests. Repeated measure
ANOVA with the Bonferroni correction was also per-
formed to examine the interactive effect between time
and EN type (Time x EN type effect) on the King’s Stool
scores change (%). Differences in non-continuous vari-
ables were analyzed with the chi-square test. Skewed
variables were log transformed prior to statistical ana-
lysis. However, for descriptive purposes, means ± SE
are presented using untransformed values. A two-
tailed P-value <0.05 was considered statistically
significant.
Results
Baseline characteristics of study participants
Table 2 presents baseline characteristics of the study
participants completed. There were no significant differ-
ences in age, height, body weight, BMI, MAC, TSF,
MAMC, BP, sex, disease history, energy intake goals,
average energy intake during the intervention, or time
taken to reach 100 % experimental EN feeding among
the three groups.
Distribution of major gastrointestinal symptoms before
and after the intervention
There were no significant differences in the baseline distri-
bution of gastrointestinal symptoms [normal, diarrhea,
constipation, or recurrent diarrhea/constipation (D/C)]
among the three EN treatment groups (Additional file 1:
Table S1). ‘diarrhea*’ or ‘constipation*’ include recurrent
D/C before the intervention, ‘diarrhea only’ indicates sub-
jects who suffered from only diarrhea without recurrent
D/C before the intervention, ‘constipation only’ indicates
subjects who suffered from only constipation without re-
current D/C before the intervention. Gastrointestinal
symptoms were daily observed for the 14 intervention
days.
Figure 1 shows improvement (%) of diarrhea according
to EN types during the intervention. Each subject group
was also subdivided into two part ‘medication user in-
cluded’ and ‘medication user excluded’. Diarrhea in the
low-FODMAP group had improved significantly more
than that in the moderate- or high-FODMAP groups after
the intervention (final improvement). This pattern was
similarly observed in each diarrhea subgroup Diarrhea im-
provements in the low-FODMAP group among subjects
with diarrhea* including or excluding medication users
were 73.3 % (P = 0.046) and 71.4 % (P = 0.028), respect-
ively, among those with diarrhea only including or exclud-
ing medication users were 60.0 % (P = 0.047) and 60.0 %
(P = 0.035), respectively. Interestingly, diarrhea improve-
ment among the subjects with diarrhea only, but no medi-
cation users was observed only in the low-FODMAP
Table 2 Baseline characteristics of study subjects
Low-FODMAP (n = 30) Moderate-FODMAP (n = 28) High-FODMAP (n = 26)
Age (years) 60.1 ± 2.92 60.6 ± 3.03 62.5 ± 2.70
Female (n, %) 9 (30.0) 9 (32.1) 8 (30.8)
Weight (kg)a 55.4 ± 2.37 56.7 ± 2.61 55.9 ± 2.48
BMI (kg/m2)a 19.9 ± 0.68 20.6 ± 0.77 20.4 ± 0.75
MAC (cm) 25.2 ± 0.53 25.4 ± 0.70 24.2 ± 0.80
TSF (mm) 11.0 ± 0.89 12.2 ± 1.04 10.1 ± 0.88
MAMC (cm) 21.8 ± 0.50 21.5 ± 0.53 21.0 ± 0.72
Systolic BP (mmHg) 111.2 ± 2.85 116.3 ± 2.21 116.5 ± 2.76
Diastolic BP (mmHg) 74.2 ± 2.52 73.5 ± 1.52 75.0 ± 1.89
Disease history
Hypertension 13 (43.3 %) 16 (57.1 %) 12 (46.2 %)
Diabetesb 5 (16.7 %) 5 (17.9 %) 6 (23.1 %)
Stroke 23 (76.7 %) 15 (53.6 %) 18 (69.2 %)
Cardiovascular disease 4 (13.3 %) 3 (10.7 %) 6 (23.1 %)
Hyperlipidemia 3 (10.0 %) 7 (25.0 %) 2 (8.00 %)
Cancer 1 (3.30 %) 1 (3.60 %) 2 (8.00 %)
Energy intake goal (kcal/day) 1273.3 ± 32.5 1310.7 ± 45.5 1269.2 ± 46.7
Average energy intake (kcal/day) 1267.2 ± 33.8 1302.6 ± 44.5 1270.5 ± 47.0
Time to reach 100 % experimental EN feeding (days) 2.57 ± 0.22 2.57 ± 0.29 2.58 ± 0.21
BMI body mass index, BP blood pressure, MAC midarm circumference, MAMC midarm muscle circumference, TSF triceps skin fold thickness
Means ± SE or n (%)
an = 62
bWell-controlled diabetes
There were no significant differences in the baseline values among the three groups
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tion (for early improvement), diarrhea showed a trend to-
wards improvement in the low-FODMAP group
compared with the moderate- and high-FODMAP groups,
but the difference did not reach statistical significance
(Fig. 1).
Constipation improvements were also observed after
the intervention but not significantly different among
the three EN treatment groups (Additional file 1:
Figure S1.A). This pattern was similarly observed in
each constipation subgroup. Although constipation
improvements seemed slightly higher in the high-
FODMAP group than the other EN groups, the differ-
ences did not reach the statistical significances, which
might be related with the small number of subjects in
these groups. As shown in Additional file 1: Figure
S1.B, diarrhea had improved greater in the low-
FODMAP group than the moderate- or high-
FODMAP groups among the subjects with recurrent
D/C. This pattern was observed in each subject group
including or excluding medication users (in the low-
FODMAP group: 80 %, P = 0.017; 100 % P = 0.030,
respectively). Constipation had improved only in the
high-FODMAP group (22.2 % of ‘the medication user
included’; 33.3 % of ‘the medication user excluded’),but which did not reach the statistical significance.
Both diarrhea and constipation were slightly improved
in the low- (20 % of ‘the medication user included’),
moderate- (40 % of ‘medication user included’; 33.3 %
of ‘the medication user excluded’) and high-FODMAP
(11.1 % of ‘medication user included’) groups, but
which were not significantly different among the
groups. Participants with normal condition at baseline
maintained this condition, except for one case occur-
rence of constipation in the moderate-FODMAP
group. A few other gastrointestinal symptoms (e.g.,
mild abdominal pain or bloating) were observed dur-
ing the intervention, but their incidence was neither
high nor significantly different among the three
groups (10.0 % in the low-FODMAP group, 10.7 % in
the moderate-FODMAP group, and 30.8 % in the
high-FODMAP group).
Changes in King’s Stool score during intervention
Data for stool assessment using the King’s Stool
scores chart were collected daily during the interven-
tion period. For graphical presentation, the observa-
tion periods were categorized into four time windows:
the adaptation period (D1–3, first three days: 0-day,
1-day, 2-day), the early period (D4–6: 3-day, 4-day, 5-
Fig. 1 Improvement (%) of diarrhea according to EN types during the intervention. Values below the graph indicate percentages. P-values were
obtained using the chi-square test: P0, p-value for differences in the improvement of diarrhea among the three EN groups within seven days from
the start of intervention (early improvement); P1, p-value for the improvement of diarrhea or constipation among the three EN groups after the
intervention (final improvement); n.s. indicates ‘statistical non-significance.’; * includes recurrent diarrhea and constipation; ‘Diarrhea only’ indicates
subjects who suffered from only diarrhea without recurrent diarrhea and constipation
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the late period (D12–14, last three days: 11-day, 12-
day, 13-day). The mean scores in each observation
period were the average values calculated from the
scores in each day during that period. Figure 2 pre-
sents % change of King’s Stool scores from the adap-
tation period (D1–3) to the early period (D4–6), the
mid period (D7–9) and late period (D12–14) in the
diarrhea subjects (Diarrhea* and ‘Diarrhea only’
groups). We also subdivided each subject group into
two part ‘medication user included’ and ‘medication
user excluded’. Repeated Measure ANOVA test was
performed to examine the interactive effect between
time and EN type (time × EN type effect) on the
King’s Stool scores change (%). As shown in the Fig. 2,
the King’s Stool scores (expressed by % changes) in
the low-FODMAP group were significantly and stead-
ily reduced during the intervention compared with
the moderate- or high-FODMAP groups, which were
observed in all of the diarrhea subgroups (all of
P-values <0.05).Alteration of anthropometric and biochemical parameters
in response to EN treatment
Anthropometric and basic biochemical parameters ac-
cording to EN treatment before and after the intervention
are presented in Table 3 and Additional file 1: Table S2.
After the intervention, BMI significantly increased in the
low- and high-FODMAP groups (P < 0.05 for both), and a
trend toward increasing was observed in the moderate-
FODMAP group (P < 0.10) (Table 3). After the interven-
tion, serum levels of uric acid were significantly reduced
in the low-FODMAP group compared with the moderate-
and high-FODMAP groups (P < 0.05; Table 3). The liver
function parameters serum AST (P < 0.01) and ALT (P <
0.05) increased significantly after the intervention in the
moderate-FODMAP group, and the kidney function par-
ameter serum BUN was significantly increased in the
high-FODMAP group (P < 0.05). However, all these values
were within the normal range (Table 3). Other anthropo-
metric parameters (e.g., weight, MAC, TSF, MAMC, and
BP) and basic biochemical parameters (e.g., HbA1C, WBC,
ALC, glucose, albumin, lipid profiles, and inflammatory
Fig. 2 Percent changes of King’s Stool scores in diarrhea subjects according to EN types during the intervention. Values are presented as means
± S.E.; statistical significance was assessed by repeated measure ANOVA with the Bonferroni correction. P: P-values for interactive effect between
time and EN type on King’s Stool scores; D1–3: adaptation period (first three days: 0-day, 1-day, 2-day); D4–6: early period (3-day, 4-day, 5-day);
D7–9: mid period (6-day, 7-day, 8-day); D12–14: late period (last three days: 11-day, 12-day, 13-day)
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the intervention in any of the three groups (Table 3 and
Additional file 1: Table S2).Alteration of short-term nutritional status in response to
EN treatment
Serum albumin levels reflect nutritional status over the
recent 20 days. As the intervention period in this study
was only 14 days, serum prealbumin and transferrin,
which reflect recent nutritional status (over the recent
2–3 days and 8–10 days, respectively), were also mea-
sured (Fig. 3). Serum levels of prealbumin increased sig-
nificantly after the intervention in all three EN groups.
By 3-day, serum prealbumin levels had significantly in-
creased in the low- and high-FODMAP groups; of note,
levels in the low-FODMAP group at 3-day had reached
the levels at 14-day. By contrast, serum transferrin levels
significantly increased after the intervention in themoderate-FODMAP group, but not in the low- or high-
FODMAP groups.
Nutritional status after the intervention, stratified by
subject condition
Study subjects were classified into five groups, according
to their condition after the intervention (unimproved,
normal-maintenance, diarrhea-improved, constipation-
improved and recurrent D/C-improved: 1) unimproved
(n = 29, no improvement from diarrhea or constipation),
2) normal maintenance (n = 22 without symptoms of diar-
rhea or constipation from the 23 subjects without symp-
toms before intervention), 3) diarrhea improved (n = 8
improvements from the 18 diarrhea-only subjects before
the intervention), 4) constipation improved (n = 13 im-
provements from the 24 constipation-only subjects before
the intervention) and 5) recurrent D/C improved (n = 12
improvements from the 19 complex condition subjects
before the intervention). Additional file 1: Table S3
Table 3 Anthropometric measurements, blood cell counts, and liver and kidney function markers before and after the intervention
Low-FODMAP (n = 30) Moderate-FODMAP (n = 28) High-FODMAP (n = 26)
Baseline After Baseline After Baseline After
Weight (kg)a 55.4 ± 2.37 55.6 ± 2.36 56.7 ± 2.61 56.3 ± 2.52 55.9 ± 2.48 55.9 ± 2.49
BMI (kg/m2)a 19.9 ± 0.68 21.3 ± 0.90* 20.6 ± 0.77 22.2 ± 1.07† 20.4 ± 0.75 22.2 ± 0.95*
MAC (cm) 25.2 ± 0.53 25.5 ± 0.58 25.4 ± 0.70 25.2 ± 0.77 24.2 ± 0.80 24.8 ± 0.66
TSF (mm) 11.0 ± 0.89 12.0 ± 0.82 12.2 ± 1.04 12.7 ± 1.00 10.1 ± 0.88 11.0 ± 0.92†
MAMC (cm) 21.8 ± 0.50 21.7 ± 0.56 21.5 ± 0.53 21.2 ± 0.66 21.0 ± 0.72 21.3 ± 0.61
Systolic BP (mmHg) 111.2 ± 2.85 110.8 ± 2.46 116.3 ± 2.21 116.8 ± 2.36 116.5 ± 2.76 117.6 ± 3.49
Diastolic BP (mmHg) 74.2 ± 2.52 74.0 ± 2.22 73.5 ± 1.52 75.7 ± 1.87 75.0 ± 1.89 74.6 ± 2.08
HbA1c (%) 5.46 ± 0.27 5.47 ± 0.34 5.52 ± 0.17 5.43 ± 0.18 5.17 ± 0.12 5.24 ± 0.13
ALC (count/μL) 1957.7 ± 132.1 1858.1 ± 83.2 1791.2 ± 123.1 1763.2 ± 121.2 1769.2 ± 137.2 1790.0 ± 147.5
WBC (×106/μL) 6.62 ± 0.42 7.17 ± 0.48 7.55 ± 0.65 7.12 ± 0.53 6.90 ± 0.54 7.84 ± 0.59
AST (U/L) 20.8 ± 1.11 20.8 ± 1.50 20.3 ± 1.25 23.3 ± 1.32** 18.6 ± 0.95 17.8 ± 0.89
ALT (U/L) 21.8 ± 2.87 21.5 ± 2.44 16.3 ± 1.29 20.2 ± 1.59* 14.3 ± 1.25 15.3 ± 1.40
Creatinine (mg/dL) 0.67 ± 0.05 0.67 ± 0.04 0.70 ± 0.07 0.72 ± 0.07 0.62 ± 0.04 0.61 ± 0.04
BUN (mg/dL) 14.1 ± 1.64 13.8 ± 1.07 13.9 ± 1.40 13.5 ± 1.41 11.7 ± 0.96 12.7 ± 1.05*
Uric acid (mg/dL) 4.48 ± 0.27 3.99 ± 0.21* 5.10 ± 0.33 4.93 ± 0.27 4.74 ± 0.29 4.47 ± 0.37
ALC absolute lymphocyte count, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, BP blood pressure, BUN blood urea nitrogen,
HbA1c glycated hemoglobin, MAC midarm circumference, MAMC midarm muscle circumference, TSF triceps skin fold thickness, WBC white blood cells
Values shown as means ± S.E
a n = 62
†p < 0.1, *p < 0.05, **p < 0.01,***p < 0.001. Differences in within-group means before and after the intervention were assessed using the paired t-test; there were
no significant differences in the baseline values among the three groups
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FODMAP EN consumption in each of subgroups: 75 % of
the diarrhea improved group consumed low-FODMAP
EN formula. 38.5 % and 46.2 % of the recurrent D/C im-
proved group consumed the low- and moderate-
FODMAP EN formulas, respectively (Additional file 1:
Table S3). As shown in Fig. 4, after the intervention, BMI
significantly increased in the normal maintenance, the
diarrhea improved, the constipation improved and the re-
current D/C improved groups, but not in the unimproved
group. TSF showed a trend toward increasing in theFig. 3 Short-term nutritional status in response to EN treatment. Values
differences was assessed by paired t-test. There were no significant diff
0.05, **P < 0.01 compared with baseline valuesdiarrhea-improved group, but it did not reach statistical
significance. Serum prealbumin levels in the diarrhea-
improved, the constipation improved and the recurrent
D/C improved groups significantly increased at 14-day.
Particularly, serum preablumin levels in the diarrhea im-
proved and the recurrent D/C improved groups were
highly increased at 3-day and continued by 14-day. In the
normal maintenance group, serum preablumin levels
tended toward increasing at 14-day, but it did not reach
statistical significance. Serum transferrin levels increased
significantly in the diarrhea improved and the recurrentpresented as means ± S.E.; statistical significance of within group
erences in baseline values among the three groups. †P < 0.1, *P <
Fig. 4 Anthropometric and nutritional status stratified by subject condition after the intervention. Values are presented as means ± S.E.;
statistical significance of within group differences was assessed by paired t-test. There were no significant differences in baseline values
among the three groups. †P < 0.1, *P < 0.05, **P < 0.01 compared with baseline values. Study subjects were categorized into 5 groups
according to their final condition during the intervention: 1) unimproved (n = 29, no improvement from diarrhea or constipation), 2)
normal maintenance (n = 22 without symptoms of diarrhea or constipation from the 23 subjects without symptoms before intervention),
3) diarrhea improved (n = 8 improvements from the 18 diarrhea-only subjects before the intervention), 4) constipation improved (n = 13
improvements from the 24 constipation-only subjects before the intervention) and 5) recurrent D/C improved (n = 12 improvements from
the 19 recurrent diarrhea and constipation subjects before the intervention)
Yoon et al. Nutrition Journal  (2015) 14:116 Page 10 of 12D/C improved groups at 14-day. By contrast, the unim-
proved group did not show any statistically significant
changes in serum levels of prealbumin or transferrin.
Discussion
This randomized, multicenter, double-blind clinical trial
shows for the first time that a low-FODMAP formula
can promptly improve diarrhea and nutritional status in
patients receiving EN. In this study, diarrhea in patients
receiving low-FODMAP EN was significantly improved
compared with those receiving moderate- or high-
FODMAP EN. King’s Stool scores in patients with diar-
rhea in the low-FODMAP group were also significantly
reduced than those in the other two groups. In addition,
serum prealbumin, a marker of short-term nutritional
status, promptly improved in patients receiving low-
FODMAP EN, in contrast to the other groups. Whensubjects were classified by condition after the interven-
tion, markers of short-term nutritional status (prealbu-
min and transferrin) were significantly improved in the
gastrointestinal symptom-improved groups, particularly
in the diarrhea-improved group. These results support
the hypothesis that low-FODMAP formula may improve
or reduce the likelihood of diarrhea in patients receiving
EN, leading to an improvement in nutritional status
helpful for prompt recovery from illness.
Diarrhea is one of the major gastrointestional prob-
lems frequently observed in hospitalized patients receiv-
ing EN [8–10]; it may cause nutritional imbalance and
consequently delay recovery [12, 17]. Many studies had
tried to improve gastrointestinal problems, particularly
diarrhea related to EN [2, 6, 9, 10, 14, 15, 32], but the
results have been inconsistent. Recent studies have re-
ported an association between gastrointestinal symptoms
Yoon et al. Nutrition Journal  (2015) 14:116 Page 11 of 12and dietary FODMAPs. Restriction of dietary FODMAPs
has been reported to improve gastrointestinal symptoms,
including diarrhea, in a majority of patients with IBS
and IBD [20–23]. Halmos et al. suggested in his retro-
spective study that receiving a lower-FODMAP formula
may reduce the likelihood of diarrhea among several
types of formulas [8]. In our present study, patients re-
ceiving a low-FODMAP EN formula showed greater im-
provements in diarrhea symptoms than those who
received a moderate- or high-FODMAP formula (im-
provement in 60.0-73.3 % of patients vs. 25.0-33.0 % and
25.0-36.4 %, respectively). After the 14-day intervention,
the low-FODMAP group also showed a much greater re-
duction in the King’s Stool score compared with the
other two groups. The mechanisms by why FODMAP
restriction provides these benefits are assumed to be re-
lated to the molecular size and osmotic properties of
FODMAPs [8, 33, 34]. FODMAPs are short-chain carbo-
hydrates which have relatively smaller molecular size
than non-short chain carbohydrates [8, 33, 34]. They are
poorly absorbed in the small intestine and rapidly fer-
mented by bacteria in the colon. Subsequent luminal
distension may lead to secondary motility disturbance
and diarrhea [23, 25]. Therefore, low-FODMAP formu-
las may result in less water retention within the lumen
of the bowel and less gas in the intestine compared with
moderate- or high-FODMAP formulas [8, 33, 34],
thereby reducing gastrointestinal symptoms, particularly
diarrhea.
In our study, compared with the other two groups, the
low-FODMAP group showed significant improvements
in serum prealbumin, a marker of short-term nutritional
status at 3-day, which continued by 14-day, and in
serum uric acid at 14-day. Additionally, patients with
improved gastrointestinal symptoms after the interven-
tion had greater BMIs than those who did not improve.
Serum levels of prealbumin and transferrin which reflect
recent nutritional status were also significantly improved
in the improved gastrointestinal symptoms groups, par-
ticularly more in the diarrhea-improved group. It may
be explained by that an improvement in diarrhea symp-
toms helps patients absorb sufficient amounts of nutri-
ents to satisfy their nutritional requirements. These
results from our randomized, double-blind, clinical trial
provide the first intervention-based evidence that low-
FODMAP formula improves diarrhea and nutritional
status in patients receiving EN, potentially improving
their nutritional status and ability to promptly recover
from illness.
Our study has a few limitations. First, it is a random-
ized, double-blind, clinical trial where subjects were ran-
domly assigned to one of three EN formulas. If each
subject had consumed all three EN formulas via a cross-
over design, our conclusions would be more stronglysupported. Second, long-term observation (i.e., for 2 to
6 months) may confirm whether the association between
FODMAP-reduced EN feeding and improved diarrhea
results in durable improvements to nutritional status
and other metabolic parameters, shortening recovery
time. Despite these limitations, this prospective interven-
tion study shows that a low-FODMAP EN formula may
improve diarrhea in patients receiving EN therapy,
thereby improving nutritional status and potentially aid-
ing prompt recovery from illness. Therefore, low-
FODMAP EN formulas are expected to provide a useful
therapeutic approach for patients with gastrointestinal
symptoms, and particularly diarrhea, who are undergo-
ing EN.
Conclusions
The results from our randomized, double-blind, clinical
trial provide the first intervention-based evidence that
low-FODMAP EN improves diarrhea and nutritional
status in patients receiving EN, potentially improving
their nutritional status and ability to promptly recover
from illness. Therefore, low-FODMAP EN formulas are
expected to provide a useful therapeutic approach for
patients with diarrhea undergoing EN.
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